Factor IX Concentrate and Viral Hepatitis
Authors: BRUCE F. BOKLAN
Journal: Annals of Internal Medicine (1971)

Letters and Comments1 February 1971Factor IX Concentrate and Viral HepatitisBRUCE F. BOKLAN, M.D.BRUCE F. BOKLAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-74-2-298_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The letter by Dr. Kingdon in the October issue (Ann Intern Med 73:656, 1970), concerning a case of viral hepatitis after the administration of a factor IX concentrate (Konȳne®, Cutter Laboratories), prompts me to record our experiences with the same product.In 1968 and 1969, before the release of Konȳne, the Hemophilia Service of the Long Island Jewish Medical Center took part in an evaluation of the material. At that time the preparation was called Hemoplex.Ten patients were treated with Hemoplex, and, within a 6-month period, four contracted clinical hepatitis. No attempt was made to determine... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Coagulation Laboratory Division of Hematology Long Island Jewish Medical Center New Hyde Park, N.Y. 11040 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByKinetics of factor IX activity differ from that of factor IX antigen in patients with haemophilia B receiving high-purity factor IX replacementFractionation of Factor VIII and IX - An Overview1 Approaches to Plasma Fractionation for Improved Recovery and the Development of Potentially Useful Clinical FactorsProduction of Hepatitis-Safe Plasma Proteins from Cold Sterilized PlasmaClinical evaluation of the hepatitis safety of a β-propiolactone/ultraviolet treated factor IX concentrate (PPSB)Evaluation of the Effect of Betapropiolactone/Ultraviolet Irradiation (BPL/UV) Treatment of Source Plasma on Hepatitis Transmission by Factor IX Complex in ChimpanzeesEfficacy of Combined Treatment of Human Plasma with β-Propiolactone and UV IrradiationProthrombin Complex Concentrates for Clinical UseBlood Component Therapy in Neonatal MedicineHepatitis risk in cardiac surgery patients receiving factor IX concentratesIncidence of Viral Hepatitis after Administration of Factor IX ConcentratesDisseminated Intravascular Coagulation and Blood Component TherapyThe Prevalence of Hepatitis-B Antigen (HBsAg) and Its Antibody (ANTI-HBs) Among London Hemophiliacs and Blood Donors from London and Two Tropical AreasAcute coagulopathy following infusion of prothrombin complex concentrateHepatitis-B: A reviewProthrombin complex concentrate: Use in controlling the hemorrhagic diathesis of chronic liver diseaseThe Use of Factor IX Concentrates for Patients with Conditions other than Factor IX DeficiencyCONCENTRATION OF HEPATITIS-B ANTIGEN FROM CLINICAL PREPARATIONS OF II, VII, IX, AND X BY POLYETHYLENE GLYCOL, TO ENHANCE DETECTION AND REMOVALBLOOD?ITS DERIVATIVES AND ITS PROBLEMS?FACTOR IXJaundice and Hepatitis B Antigen/Antibody in HemophiliaProthrombin Complex Concentrates in Acquired HypoprothrombinemiaS. G. SANDLER, M.D., F.A.C.P., C. E. RATH, M.D., F.A.C.P., A. RUDER, M.D.Post-Konyne Hepatitis: The Ineffectiveness of Screening for the Hepatitis B Antigen (HBAg)Hepatitis after konyne administrationne administrationDevelopment of Large-Scale Fractionation MethodsAnaphylaxis after KonyneHepatitis after Konyne Administration 1 February 1971Volume 74, Issue 2Page: 298-298KeywordsHemophiliaHepatitis A Issue Published: 1 February 1971 PDF DownloadLoading ...